Jordan (@Jordan090180) profile picture
Joined October 2026
Photo by Jordan (@Jordan090180)Photo by Jordan (@Jordan090180)
$NWBO, This is why everyone should be worried. As long as Danish continues to post the stock is bound to go down. He has been throwing this BS of I am not worried for many years. If folks listened to his crap, they would be down 90%+ and lost years of opportunity cost. $NWBO
13
$NWBO Expect the short interest to go up as soon as the September CHM minutes are released. It’s clear they didn’t appear at October CHM. December is a tax loss selling month for baggies. Plus LP diluting 40M+ shares per month. All of this adds fuel to the fire! ;) $NWBO
45
$NWBO, 50%+ downside is on the cards in the next month or two as efficacy concerns loom. Tax loss selling approaching next month. Then around mid 2027 one can expect a request for increase in billion odd shares. That would again be an excellent opportunity to make easy money! ;)
65
$NWBO, it becomes increasingly clear that the new & previous IR persons (Richard and GZ) lied to a few shareholders. Even though they knew that $NWBO didn't appear at Sept CHM they lied that they expect a decision before Nov 15 10-Q. Why would anyone trust these BS artists? $NWBO
1
133
$NWBO All time lows and another 50% downside coming before the end of the year with December being the tax loss selling month for $NWBO over the years! ;) $NWBO
75
NHSBT announces collaboration with companies during various development phase including early clinical trials. Check out NephStrom & Orbsen Therapeutics. Both are cell therapy companies with NHSBT collaboration agreement for many years but no approvals. Sure there are more! $NWBO
189
$NWBO If MHRA rejects DCVax-L, shareholders could face devastating losses with little hope of recovery. Ironically, conditional approval might offer shareholders two opportunities: sell into the initial spike & profit again by shorting the subsequent decline. $NWBO 1/3
11
5
2,026
If MHRA grants conditional approval at some point in 2027 and the stock spikes to $0.30–$0.40 that would create a decent short opportunity. Even better if it rallies to $0.50–$0.60. This provides even greater return on both sides. $NWBO 2/3
2
409
With limited commercial prospects, ongoing cash burn, & LP's track record of dilution & missed expectations, a slide back below $0.10 within a couple quarters is something you can absolutely count on. Get ahead of LP’s excuses, flawed execution & predatory financiers! $NWBO 3/3
3
454
$NWBO September CHM minutes should be out in the next 2 weeks. Will pumpers & the new IR (Richard) person’s lies be exposed when it becomes clear that $NWBO was not discussed? We already know that they didn’t appear in Oct. Tax loss selling window is also approaching! ;) $NWBO
1
124
$NWBO “But the challenge is trying to determine which patients it may work for & for which patients it doesn’t.” By LL from the latest UCLA article. This is what MHRA has been dealing with for almost 3 years. No wonder $NWBO hasn’t submitted reimbursement evidence. Too bad. $NWBO
111
$NWBO Why no commercial team (sales, marketing, etc.) hiring in the UK? Biotechs big or small hire these teams months in advance of regulatory approval. See you in 2027 with $NWBO still withholding material info but likely fighting a shareholder lawsuit. Doesn’t look good. $NWBO
1
103
You only shitpost on NWBO. And only started existing last month. You have a wealth of long term information on the company for some reason. But decided to start commenting 30 days ago nonstop. And apparently now you know about current financiers actions. Settle down AF. Lmao. Lmao. 😂😂
1
1
14
187
$NWBO In its October 26 PR, NWBO identified 2 priorities: (1) expanding manufacturing capacity, including restarting US production as UK backup, &(2) preparing trials for cancers beyond GBM. The glaring omission? No mention of preparing a US FDA BLA for DCVax-L. Why? 1/4
4
1
967
Instead, could the focus on US backup capacity & additional trials suggest management anticipates very restricted/conditional UK approval at best, potentially requiring further clinical evidence generation? That could explain the apparent lack of US BLA preparations. 3/4
1
132
If MHRA (most supportive RA) still has efficacy concerns, FDA would likely reject. Otherwise, seeking revenue from the biggest & most profitable market by far would be the highest priority rather than running another trial when you’ve been diluting endlessly in pennies. $NWBO
152
$NWBO Will the POS management crew finally disclose the provisional CHM letter (efficacy) concerns in the upcoming quarterly this week or will they continue to withhold material info from shareholders? Is a shareholder lawsuit likely next month? It will be interesting. $NWBO
1
158
$NWBO, How low does $NWBO go as tax loss selling season approaches? Plus, its clear from August CHM minutes & the UK parliament pleading that there will be at least 6 month clock off from $NWBO. So even Q1 2027 will come & go. Another 50%+ downside? LP’s financiers would know!
1
2
1
2
1,673
$NWBO Flipper on iHub BSing about a new hire Michael Frank Vasilios. Apparently he works for Donohoe Advisory Associates, & is just a consultant to NWBO. They had consultants who were experts with NYSE before and it lead to nothing. Flipper has a 13+ year history of BS & lies.
148